Dengue, caused by infection of any of four dengue virus serotypes (DENV-1 to DENV-4), is a
mosquito-borne disease of major public health concern associated with significant morbidity …

Dengue virus poses a major threat to global public health: two-thirds of the world's
population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a …

Background Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is
under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously …

Background A substantial unmet need remains for safe and effective vaccines against
dengue virus disease, particularly for individuals who are dengue-naive and those younger …

Dengue virus (DENV) is a mosquito-transmitted RNA virus that infects an estimated 390
million humans each year. Here, we review recent advances in our understanding of the …

Background Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy
study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Dengue is the most common arboviral disease caused by one of four distinct but closely
related dengue viruses (DENV) and places significant economic and public health burdens …

Status of vaccine research and development of vaccines for dengue - ScienceDirect Skip to
main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …

Background An unmet medical need remains for an effective dengue tetravalent vaccine that
can be administered irrespective of previous dengue exposure. TAK-003, a dengue …